Dual inhibition of Mcl-1 by the combination of carfilzomib and TG02 in multiple myeloma

References

• Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA: Cancer J Clin 2014; 64:9-29; PMID:24399786; http://dx.doi.org/10.3322/caac.21208
   PubMed Web of Science ®Google Scholar
• Andreu-Vieyra C, Berenson JR. Carfilzomib in multiple myeloma. Exp Opin biol Ther 2014; 11:1685–1699; PMID: 25170966; http://dx.doi.org/10.1517/14712598.2014.953050v
   PubMed Web of Science ®Google Scholar
• Zang Y, Thomas SM, Chan ET, Kirk CJ, Freilino ML, DeLancey HM, Grandis JR, Li C, Johnson DE. Carfilzomib and ONX 0912 inhibit cell survival and tumor growth of head and neck cancer and their activities are enhanced by suppression of Mcl-1 or autophagy. Clin Cancer Res: Off J Am Assoc Cancer Res 2012; 18:5639-49; PMID:22929803; http://dx.doi.org/10.1158/1078-0432.CCR-12-1213
   PubMed Web of Science ®Google Scholar
• Lonial S, Boise LH. The future of drug development and therapy in myeloma. Semin Oncol 2013; 40:652-8; PMID:24135409; http://dx.doi.org/10.1053/j.seminoncol.2013.07.004
   PubMed Web of Science ®Google Scholar
• Moreau P. The emerging role of carfilzomib combination therapy in the management of multiple myeloma. Exp Rev Hematol 2014; 7:265-90; PMID:24521249; http://dx.doi.org/10.1586/17474086.2014.873699
   PubMed Web of Science ®Google Scholar
• Tiburzy B, Kulkarni U, Hauser AE, Abram M, Manz RA. Plasma cells in immunopathology: concepts and therapeutic strategies. Semin Immunopathol 2014; 36:277-88; PMID:24740168; http://dx.doi.org/10.1007/s00281-014-0426-8
   PubMed Web of Science ®Google Scholar
• Delgado ME, Dyck L, Laussmann MA, Rehm M. Modulation of apoptosis sensitivity through the interplay with autophagic and proteasomal degradation pathways. Cell Death Dis 2014; 5:e1011; PMID:24457955; http://dx.doi.org/10.1038/cddis.2013.520
   PubMed Web of Science ®Google Scholar
• Fennell DA, Chacko A, Mutti L. BCL-2 family regulation by the 20S proteasome inhibitor bortezomib. Oncogene 2008; 27:1189-97; PMID:17828309; http://dx.doi.org/10.1038/sj.onc.1210744
   PubMed Web of Science ®Google Scholar
• Boise LH, Kaufman JL, Bahlis NJ, Lonial S, Lee KP. The Tao of myeloma. Blood 2014; 124:1873-9; PMID:25097176; http://dx.doi.org/10.1182/blood-2014-05-578732
   PubMed Web of Science ®Google Scholar
• Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM, Demo SD, Bennett MK, van Leeuwen FW, Chanan-Khan AA, et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood 2007; 110:3281-90; PMID:17591945; http://dx.doi.org/10.1182/blood-2007-01-065888
   PubMed Web of Science ®Google Scholar
• Obeng EA, Carlson LM, Gutman DM, Harrington WJ Jr, Lee KP, Boise LH. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006; 107:4907-16; PMID:16507771; http://dx.doi.org/10.1182/blood-2005-08-3531
   PubMed Web of Science ®Google Scholar
• Jacquemont C, Taniguchi T. Proteasome function is required for DNA damage response and fanconi anemia pathway activation. Cancer Res 2007; 67:7395-405; PMID:17671210; http://dx.doi.org/10.1158/0008-5472.CAN-07-1015
   PubMed Web of Science ®Google Scholar
• Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell 2004; 116:205-19; PMID:14744432; http://dx.doi.org/10.1016/S0092-8674(04)00046-7
   PubMed Web of Science ®Google Scholar
• Lakhani SA, Masud A, Kuida K, Porter GA Jr, Booth CJ, Mehal WZ, Inayat I, Flavell RA. Caspases 3 and 7: key mediators of mitochondrial events of apoptosis. Science (New York, NY) 2006; 311:847-51; PMID:NOT_FOUND; http://dx.doi.org/10.1126/science.1115035
   PubMedGoogle Scholar
• Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol 2007; 35:495-516; PMID:17562483; http://dx.doi.org/10.1080/01926230701320337
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg Robert A. Hallmarks of cancer: the next generation. Cell 2011; 144:646-74; PMID:21376230; http://dx.doi.org/10.1016/j.cell.2011.02.013
   PubMed Web of Science ®Google Scholar
• Le Gouill S, Podar K, Harousseau JL, Anderson KC. Mcl-1 regulation and its role in multiple myeloma. Cell Cycle (Georgetown, Tex) 2004; 3:1259-62; PMID:15467463; http://dx.doi.org/10.4161/cc.3.10.1196
   PubMed Web of Science ®Google Scholar
• Derenne S, Monia B, Dean NM, Taylor JK, Rapp MJ, Harousseau JL, Bataille R, Amiot M. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood 2002; 100:194-9; PMID:12070027; http://dx.doi.org/10.1182/blood.V100.1.194
   PubMed Web of Science ®Google Scholar
• Zhang B, Gojo I, Fenton RG. Myeloid cell factor-1 is a critical survival factor for multiple myeloma. Blood 2002; 99:1885-93; PMID:11877256; http://dx.doi.org/10.1182/blood.V99.6.1885
   PubMed Web of Science ®Google Scholar
• Morales AA, Gutman D, Lee KP, Boise LH. BH3-only proteins Noxa, Bmf, and Bim are necessary for arsenic trioxide-induced cell death in myeloma. Blood 2008; 111:5152-62; PMID:18354037; http://dx.doi.org/10.1182/blood-2007-10-116889
   PubMed Web of Science ®Google Scholar
• Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T, Tokino T, Taniguchi T, Tanaka N. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science (New York, NY) 2000; 288:1053-8; PMID:10807576; http://dx.doi.org/10.1126/science.288.5468.1053
   Web of Science ®Google Scholar
• Day CL, Chen L, Richardson SJ, Harrison PJ, Huang DC, Hinds MG. Solution structure of prosurvival Mcl-1 and characterization of its binding by proapoptotic BH3-only ligands. J Biol Chem 2005; 280:4738-44; PMID:15550399; http://dx.doi.org/10.1074/jbc.M411434200
   PubMed Web of Science ®Google Scholar
• Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG, Colman PM, Day CL, Adams JM, Huang DC. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 2005; 17:393-403; PMID:15694340; http://dx.doi.org/10.1016/j.molcel.2004.12.030
   PubMed Web of Science ®Google Scholar
• Parlati F, Lee SJ, Aujay M, Suzuki E, Levitsky K, Lorens JB, Micklem DR, Ruurs P, Sylvain C, Lu Y, et al. Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. Blood 2009; 114:3439-47; PMID:19671918; http://dx.doi.org/10.1182/blood-2009-05-223677
   PubMed Web of Science ®Google Scholar
• Gupta VA, Nooka AK, Lonial S, Boise LH. Clinical potential of carfilzomib in the treatment of relapsed and refractory multiple myeloma. Blood Lymphatic Cancer: Targets Ther 2013; 41-51; http://dx.doi.org/10.2147/BLCTT.431876
   Google Scholar
• Shah JJ, Stadtmauer EA, Abonour R, Cohen AD, Bensinger WI, Gasparetto C, Kaufman JL, Lentzsch S, Vogl DT, Orlowski RZ, et al. A multi-center phase I/II trial of carfilzomib and pomalidomide with dexamethasone (Car-Pom-d) in patients with relapsed/refractory multiple myeloma. ASH Annual Meeting Abstracts 2012; 120:74
   Google Scholar
• Kaufman JL, Zimmerman T, Rosenbaum CA, Nooka AK, Heffner LT, Harvey RD, Gleason C, Lewis C, Sharp C, Barron KW, et al. Phase I study of the combination of carfilzomib and panobinostat for patients with relapsed and refractory myeloma: a multiple myeloma research consortium (MMRC) clinical trial. ASH Annual Meeting Abstracts 2014; 124:32
   Google Scholar
• Lonial S, Kaufman JL. The era of combination therapy in myeloma. J Clin Oncol: Off J Am Soc Clin Oncol 2012; 30:2434-6; PMID:22585685; http://dx.doi.org/10.1200/JCO.2011.40.6967
   PubMed Web of Science ®Google Scholar
• Lonial S, Mitsiades CS, Richardson PG. Treatment options for relapsed and refractory multiple myeloma. Clin Cancer Res: Off J Am Assoc Cancer Res 2011; 17:1264-77; PMID:21411442; http://dx.doi.org/10.1158/1078-0432.CCR-10-1805
   PubMed Web of Science ®Google Scholar
• Orlowski RZ, Nagler A, Sonneveld P, Blade J, Hajek R, Spencer A, San Miguel J, Robak T, Dmoszynska A, Horvath N, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol: Off J Am Soc Clin Oncol 2007; 25:3892-901; PMID:17679727; http://dx.doi.org/10.1200/JCO.2006.10.5460
   PubMed Web of Science ®Google Scholar
• Pasha MK, Jayaraman R, Reddy VP, Yeo P, Goh E, Williams A, Goh KC, Kantharaj E. Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor. Drug Metab Lett 2012; 6:33-42; PMID:22372550; http://dx.doi.org/10.2174/187231212800229336
   PubMedGoogle Scholar
• Goh KC, Novotny-Diermayr V, Hart S, Ong LC, Loh YK, Cheong A, Tan YC, Hu C, Jayaraman R, William AD, et al. TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties. Leukemia 2012; 26:236-43; PMID:21860433; http://dx.doi.org/10.1038/leu.2011.218
   PubMed Web of Science ®Google Scholar
• Pallis M, Abdul-Aziz A, Burrows F, Seedhouse C, Grundy M, Russell N. The multi-kinase inhibitor TG02 overcomes signalling activation by survival factors to deplete MCL1 and XIAP and induce cell death in primary acute myeloid leukaemia cells. Brit J Haematol 2012; 159:191-203; PMID:22934750; http://dx.doi.org/10.1111/bjh.12018
   PubMed Web of Science ®Google Scholar
• Alsina M, Trudel S, Furman RR, Rosen PJ, O'Connor OA, Comenzo RL, Wong A, Kunkel LA, Molineaux CJ, Goy A. A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma. Clin Cancer Res: Off J Am Assoc Cancer Res 2012; 18:4830-40; PMID:22761464; http://dx.doi.org/10.1158/1078-0432.CCR-11-3007
   PubMed Web of Science ®Google Scholar
• Zhong Q, Gao W, Du F, Wang X. Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis. Cell 2005; 121:1085-95; PMID:15989957; http://dx.doi.org/10.1016/j.cell.2005.06.009
   PubMed Web of Science ®Google Scholar
• Opferman JT. Unraveling MCL-1 degradation. Cell Death Diff 2006; 13:1260-2; PMID:16710358; http://dx.doi.org/10.1038/sj.cdd.4401978
   PubMed Web of Science ®Google Scholar
• Walsby E, Pratt G, Shao H, Abbas AY, Fischer PM, Bradshaw TD, Brennan P, Fegan C, Wang S, Pepper C. A novel Cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabine. Oncotarget 2014; 5:375-85; PMID:24495868; http://dx.doi.org/10.18632/oncotarget.1568
   PubMed Web of Science ®Google Scholar
• Hong SE, Kim EK, Jin HO, Kim HA, Lee JK, Koh JS, Seol H, Kim JI, Park IC, Noh WC. S6K1 inhibition enhances tamoxifen-induced cell death in MCF-7 cells through translational inhibition of Mcl-1 and survivin. Cell Biol Toxicol 2013; 29:273-82; PMID:23942996; http://dx.doi.org/10.1007/s10565-013-9253-2
   PubMed Web of Science ®Google Scholar
• Kim SM, Yun MR, Hong YK, Solca F, Kim JH, Kim HJ, Cho BC. Glycolysis inhibition sensitizes non-small cell lung cancer with T790M mutation to irreversible EGFR inhibitors via translational suppression of Mcl-1 by AMPK activation. Mol Cancer Therap 2013; 12:2145-56; PMID:23883584; http://dx.doi.org/10.1158/1535-7163.MCT-12-1188
   PubMed Web of Science ®Google Scholar
• Zhou T, Li G, Cao B, Liu L, Cheng Q, Kong H, Shan C, Huang X, Chen J, Gao N. Downregulation of Mcl-1 through inhibition of translation contributes to benzyl isothiocyanate-induced cell cycle arrest and apoptosis in human leukemia cells. Cell Death Dis 2013; 4:e515; PMID:23449451; http://dx.doi.org/10.1038/cddis.2013.41
   PubMedGoogle Scholar
• Alvarez-Fernandez S, Ortiz-Ruiz MJ, Parrott T, Zaknoen S, Ocio EM, San Miguel J, Burrows FJ, Esparis-Ogando A, Pandiella A. Potent antimyeloma activity of a novel ERK5/CDK inhibitor. Clin Cancer Res: Off J Am Assoc Cancer Res 2013; 19:2677-87; PMID:23532886; http://dx.doi.org/10.1158/1078-0432.CCR-12-2118
   PubMed Web of Science ®Google Scholar
• Morales AA, Kurtoglu M, Matulis SM, Liu J, Siefker D, Gutman DM, Kaufman JL, Lee KP, Lonial S, Boise LH. Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells. Blood 2011; 118:1329-39; PMID:21659544; http://dx.doi.org/10.1182/blood-2011-01-327197
   PubMed Web of Science ®Google Scholar
• Hofmeister CC, Berdeja JG, Vesole DH, Suvannasankha A, Parrott T, Abonour R. TG02, an Oral CDK9-inhibitor, in combination with carfilzomib demonstrated objective responses in carfilzomib refractory multiple myeloma patients. Blood 2015; 126:3052
   Web of Science ®Google Scholar